Send to

Choose Destination
Gene Ther. 2017 Sep;24(9):514-519. doi: 10.1038/gt.2017.45. Epub 2017 May 31.

Therapeutic approaches for spinal muscular atrophy (SMA).

Author information

The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.
Department of Pediatric Neurology, Nemours Children's Hospital, College of Medicine, University of Central Florida, Orlando, FL, USA.
Department of Pediatric Neurology, Catholic University and Centro Nemo, Policlinico Gemelli, Rome, Italy.


Spinal muscular atrophy is an autosomal recessive neurodegenerative disorder characterized by progressive muscle wasting and loss of muscle function due to severe motor neuron dysfunction, secondary to mutations in the survival motor neuron 1 (SMN1) gene. A second neighboring centromeric gene, SMN2, is intact in all patients but contains a C-to-T variation in exon 7 that affects a splice enhancer and determines exclusion of exon 7 in the majority of its transcript, leading to an unstable protein that cannot substitute for mutant SMN1. Following successful studies on disease models and intensive studies on SMN functions in the past decade, SMN upregulation targeting SMN2, has been suggested as a possible therapeutic approach. Recently, we have witnessed an historical turning point with the first disease-modifying treatment receiving Food and Drug Administration approval and now being available to patients also outside the clinical trial. This innovative treatment is an antisense oligonucleotide, which, administered intrathecally, is able to increase exon 7 inclusion in the majority of the SMN2 mRNA and increase the production of fully functional SMN protein. Alternative advanced therapies, such as viral vector mediated gene therapy and orally available small molecules, are also showing promising results in early clinical trial phases.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center